Medpage Today on MSN23h
6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases SchizophreniaA study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...
Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate ...
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
Neumora Therapeutics’ phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary endpoint
Watertown, Massachusetts Friday, January 3, 2025, 18:00 Hrs [IST] ...
Navacaprant failed to meet both primary and secondary endpoints in the study, which led to Neumora's stock plummeting approximately 80%, a stark contrast to the 2% gain in the XBI biotech index.
On Friday, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating on Neumora Therapeutics (NASDAQ:NMRA) with a steady price target of $20.00, despite the company's recent setback with its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback